Non-Hodgkin's Lymphoma

Examining Health Policy, Payer, Provider, and Patient Perspectives in Indolent Non-Hodgkin’s Lymphoma

During this highly interactive session, panelists and experts representing policy makers, payers, providers, and patients will debate key challenges in iNHL management in light of recent health policy changes, new value-based models of care delivery, and unprecedented advances in targeted therapi

Optimizing Patient Outcomes - Transitioning CAR T-Cell and Bispecific Therapies to the Outpatient Setting

Treatment with CAR T-cell and bispecific therapies is a labor-intensive process and requires substantial interprofessional collaboration. Additional education and training of all involved clinical staff is essential to managing these patients as well as their subsequent toxicities.

Archived NCCN Tumor Boards: T-Cell Engager Therapy for Diffuse Large B-Cell Lymphoma: Bispecific Antibodies for Relapsed/Refractory Disease

T-cell engager therapy with bispecific antibodies is emerging as a promising treatment option for patients with heavily pretreated DLBCL. Careful monitoring of adverse events and implementing appropriate supportive care strategies is important to maximize the clinical benefit.

Diffuse Large B-Cell Lymphoma: Sequencing Therapy for Relapsed/Refractory Disease

The advent of novel targeted therapies represents a major paradigm shift for management of relapsed or refractory diffuse large B-cell lymphomas (DLBCL).

Debate: Is the Addition of Polatuzumab Vedotin the New Standard First-Line Therapy for Diffuse Large B-Cell Lymphoma?

Polatuzumab vedotin in combination with R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) has emerged as a new first-line therapy option for patients with advanced stage diffuse large B-cell lymphomas (DLBCL).

Optimizing the Use of Bispecific Antibodies in Hematologic Malignancies

Immunotherapy using antibody drug conjugates, immune check point inhibitors, and chimeric antigen receptor (CAR) T-cells has significantly transformed the treatment landscape of relapsed or refractory hematologic malignancies.

CAR T-Cell Therapies in Hematologic Malignancies: Challenges and Strategies

Multiple CAR T-cell therapies are approved for the treatment of certain relapsed or refractory hematologic malignancies with promising clinical outcomes. However, treatment with CAR T-cell therapy is not without risk and can result in severe and potentially fatal toxicities.

Management of TP53 Mutated Mantle Cell Lymphoma

Classical mantle cell lymphoma (MCL) with TP53 mutation is associated with inferior survival outcomes to induction chemoimmunotherapy and autologous hematopoietic cell transplant, especially in younger patients.

Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma

Follicular lymphoma (FL) is characterized by multiple recurrences requiring retreatment. In recent years, EZH2 inhibitors and chimeric antigen receptor (CAR) T-cell therapies have been approved for relapsed/refractory FL after ≥2 prior systemic therapy regimens.

NCCN Tumor Boards: T-Cell Engager Therapy for Diffuse Large B-Cell Lymphoma: Bispecific Antibodies for Relapsed/Refractory Disease